CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Multispecifics are transforming the CDMO development architecture

Neutral
AI Analysis

Summary

Article discusses how manufacturers are transitioning from monoclonal antibody platforms to multispecific drug development, requiring advances in molecular engineering, analytics, and bioprocessing capabilities.

Importance:2/10
Sentiment:
0.00
CDMOmultispecificsmanufacturingmolecular engineeringbioprocessing
Related Companies

Read the original article

Published by BioSpace on August 28, 2026 7:00 AM

Read Original